Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768888 | 0.90 | MCHR1 (0.44) | MCHR1CHRM2HDAC6OPRM1ADRB2 | |
| SCHEMBL769263 | 0.90 | MCHR1 (0.44) | MCHR1CHRM2HDAC6OPRM1ADRB2 | |
| SCHEMBL768102 | 0.88 | OPRM1 (0.41) | MCHR1OPRM1SLC2A1OPRD1 | |
| SCHEMBL769141 | 0.88 | MCHR1 (0.44) | MCHR1CHRM2OPRM1ADRB2CHRM3 | |
| SCHEMBL768753 | 0.87 | MCHR1 (0.42) | MCHR1CHRM2OPRM1ADRB2CHRM3 | |
| SCHEMBL768438 | 0.86 | MCHR1 (0.44) | MCHR1CHRM2HDAC6OPRM1ADRB2 | |
| SCHEMBL768357 | 0.85 | MCHR1 (0.39) | MCHR1CHRM2HDAC6OPRM1ADRB2 | |
| SCHEMBL768948 | 0.84 | MCHR1 (0.43) | MCHR1CHRM2 | |
| SCHEMBL768446 | 0.84 | MCHR1 (0.38) | MCHR1CHRM2OPRM1CHRM3DRD2 | |
| SCHEMBL767544 | 0.84 | CHRM2 (0.41) | MCHR1CHRM2ADRB2CHRM3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | MCHR1 239/4885CHRM2 2/4885HDAC6 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.